Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults

Major Depressive Disorder Clinical Trial

— ACHIEVE2  

Official title:

Optimizing Outcomes in Older Adults With Low Back Pain and Depression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00696293
• Other study ID #: KL2RR024154
• Status: Completed
• Phase: Phase 4
• First received: June 9, 2008
• Last updated: January 30, 2017
• Start date: May 2007
• Est. completion date: April 2010

Study information

• Verified date: January 2017
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The following primary hypotheses will be tested:

1. During Step 1: Major Depressive Disorder (MDD) or Chronic Low Back Pain (CLBP) in < 40% of the initial 60 subjects treated with duloxetine (DUL) + Clinical Management(CM) during the first 8 weeks will respond (response is defined as a Montgomery Asberg Depression Rating Scale (MADRS) score </=9 and at least a 30% improvement in back pain as measured with the 20-point numeric rating scale.

2. During Step 2: More DUL+Problem Solving Therapy for Depression and Pain (PST-DP) than DUL+CM treated subjects will achieve response during the second 8 weeks, defined as a MADRS score </=9 and at least a 30% improvement in back pain as measured with the 2-point numeric rating scale.

3. Improvement in depression scores will be correlated with improvement in CLBP scores.

The exploratory hypotheses to be tested are that:

During Step 2: Compared to subjects treated with DUL+CM, subjects treated with DUL+PST-DP will have improved outcomes in: 1) disability, 2) sleep, 2) functioning/quality of life, 3) caregiver burden/depression, and 5) analgesic use.

Description:

This is a two-part study. Step 1 is an 8-week long open-label trial of duloxetine (DUL) + clinical management (CM), titrated up to 90 mg/day, for older adults with comorbid major depressive disorder (MDD) and chronic low back pain (CLBP). At week 8, if subjects have not responded, the dose of duloxetine is increased to 120 mg/day. Duloxetine will be increased and continued at 120 mg/day (or highest tolerated dose) for both randomized study groups (during step 2) to assure medication parity.

Step two starts at week 9 and includes those subjects whose MDD and/or CLBP has not met criteria for response during Step 1. At week 9 subjects will be randomized to receive treatment with either: 1) DUL 120 mg/day (or the highest tolerated dose)+ Problem Solving for Depression and Pain (PST-DP) or 2) DUL 120 mg/day (or highest tolerated dose) + CM. Step 2 will be delivered over the course of 8-10 sessions.

NOTE ADDED 1/5/16: THIS WAS TREATMENT DEVELOPMENT WORK CONDUCTED AS PART OF A CAREER DEVELOPMENT AWARD. ONLY THE FIRST OPEN-LABEL PART OF THE STUDY WAS COMPLETED, AND THESE RESULTS HAVE BEEN PUBLISHED AND WILL BE REPORTED HERE ON CLINICALTRIALS.GOV

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: April 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Age >/= 60

• Current episode of MDD per SCID DSM-IV criteria

• Must score >/= 16 on the CES-D assessment

• Serum sodium >/=130 mEq/ml

• CLBP of at least moderate severity for more days than not for >/= 3 months

• MADRS score >/= 15

• Sufficiently medically stable to be able to participate in a depression treatment protocol

• Willingness and ability to speak English Access to translators is limited. It would be unsafe to treat an older adult who does not speak English with an antidepressant and not be able to effectively communicate with them about their progress and any side effects. We provide a 24/7 on-call service for all subjects enrolled in this study. The on-call clinicians and physicians are not bilingual, and if a problem arose, it may be impossible to effectively interpret and manage the emergent situation. Finally, many of the assessments used in the study are self-reports. At the present time, we do not have the ability to translate these instruments into other languages. If the subject cannot read and understand English, this would interfere with their ability to complete the self-report assessments

• Willingness to discontinue other antidepressants and anxiolytics, except for lorazepam up to 2 mg/day

• Mini Mental State Exam > 20

• Willingness to provide informed consent

• Corrected visual ability that enables reading of newspaper headlines and hearing capacity that is adequate to respond to a raised conversational voice.

Exclusion Criteria:

• Meet DSM-IV criteria for dementia

• History of bipolar, schizophrenia, schizoaffective, or other psychotic disorder

• Alcohol or other drug abuse (including abuse of prescription medications) within the past 6 months

• History of treatment non-adherence in other protocols run by the Mid-Life or Late-Life Centers

• Acute pain superimposed on chronic pain. For example, subjects who report "red flags" which suggest a herniated disk, vertebral fracture, infection, cauda equina syndrome, or other medical emergency will be excluded

• Wheelchair bound

• History of documented non-response to duloxetine

• Concurrent use of thioridazine

• Active suicidal ideation with plan

• Uncontrolled narrow angle glaucoma

Related Conditions & MeSH terms

• Aged
• Back Pain
• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Low Back Pain
• Major Depressive Disorder

Intervention

Drug:
• Duloxetine
Duloxetine up to 120 mg/day + Clinical Management

Locations

Country	Name	City	State
United States	University of Pittsburgh School of Medicine	Pittsburgh	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
University of Pittsburgh	Eli Lilly and Company, National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Karp JF, Weiner DK, Dew MA, Begley A, Miller MD, Reynolds CF 3rd. Duloxetine and care management treatment of older adults with comorbid major depressive disorder and chronic low back pain: results of an open-label pilot study. Int J Geriatr Psychiatry. 2 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Montgomery Asberg Depression Rating Scale(MADRS) Score From Baseline and 12 Weeks	The MADRS is a rating of depression severity with theoretical scale range 0-60, with lower values representing better outcome; Larger reduction between MADRS from baseline to 12 weeks would represent better outcome	baseline and 12 weeks
Primary	Change in McGill Pain Questionaire, Short Form, Score From Baseline and 12 Weeks	The McGill Pain Questionaire, short form consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. The McGill Pain Questionaire score ranged from 0 (none) to 45 (severe).; A larger reduction of the score from baseline to 12 weeks would represent a better outcome	Baseline and 12 weeks